Cape Fear BioCapital Fund I

Cape Fear BioCapital

Status

ACTIVE

Global HQ

Durham, United States

Countries of investment

United States

Investment stages

Pre-Seed
Seed
Series A

Industries

Therapeutics
Biotech
Life Sciences
Drug Discovery
Medical Technology

About
Cape Fear BioCapital is a Durham-based venture capital firm focused on backing next-generation therapeutics companies emerging from North Carolina's research ecosystem. Their focus spans therapeutics, biotech, life sciences, and drug discovery across the United States. The firm supports NC-rooted life science founders from pre-seed through Series A stages.

Min check size: $500K
Max check size: $2M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Cape Fear BioCapital is a pre-seed to Series A stage venture capital firm deploying capital across therapeutics, biotech, life sciences, and drug discovery sectors. They partner with founders at earliest stages before most institutional capital is available, focusing on North Carolina-rooted therapeutics companies leveraging Duke, UNC, NC State, and broader NC life sciences corridor. The firm differentiates itself through Managing Partner Jimmy's 30+ years experience leading NC life science enterprises plus Dave's 15+ years as founder/CSO of Locus Biosciences (spun out of NC State & Duke with $150M+ raised).

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2024. Team of 3-4 members including 3 partners based in Durham, North Carolina. Led by Jimmy (Managing Partner, 30+ years experience founding and leading NC life science enterprises including Managing Director of Carolina Research Ventures, a university venture fund with 3 side funds and 15+ investments in early-stage companies) and Dave (Partner, 15+ years as founder/scientist/executive in Research Triangle life sciences, co-founder and former CSO of Locus Biosciences, a venture-backed biotech spun out of NC State & Duke with over $150M raised). Focused on backing therapeutics companies emerging from North Carolina's research ecosystem including Duke, UNC, NC State, and broader NC life sciences corridor. Portfolio includes Incyclix Bio, Ten63 Therapeutics, and iOrganBio.